促红细胞生成素及其受体在肿瘤中的表达及作用研究进展  

Research Advances in Expression and Function of Erythropoietin and Erythropoietin Receptor in Tumors

作　　者：孔令英[1] 晋雯[1] 

机构地区：[1]福建医科大学基础医学院病理学系,福州350004

出　　处：《医学综述》2011年第5期698-700,共3页Medical Recapitulate

摘　　要：促红细胞生成素(EPO)最早被发现只在胎肝及成人肾脏中合成,可以促进红系集落形成单位的有丝分裂和增殖,并向形态可识别的前体细胞分化。研究发现,EPO及其受体(EPO-R)在多种不同非造血器官及组织中表达,并发挥组织保护、免疫调节、促进血管增生等作用。临床上已经成功地将重组的促红细胞生成素用于治疗肿瘤相关贫血等疾病。最新多项研究发现,在多种恶性肿瘤组织细胞中存在EPO及EPO-R的表达。Erythropoietin was firstly found to be synthesized by fetal hepatocytes and human kidney,and it could stimulate the mitosis,proliferation,and differentiation into recognizable blood precursors of colony-forming unit-erythrocyte.Recent researches have shown EPO and its receptor（erythropoietin receptor,EPO-R）express in many nonhematopoietic organs and multiple tissues,and exert tissue-protective,immunoregulatory and angiogenic effects in human body.Recombinant human erythropoietin（rh-EPO）has been successfully used in clinic to treat malignancy-associated anemia and other diseases.A series of studies have reported that EPO and EPO-R also express in various tumor cells.

关 键 词：促红细胞生成素 受体 作用 肿瘤 

分 类 号：R73[医药卫生—肿瘤]